Peptide Initiative

Peptide history · 2018

Mazdutide (IBI362)

The Chinese Biotech That Beat The World to a New Drug Class

Approved (China)2011 – 2027-2028

A young Chinese company races against global giants to develop the world's first dual GLP-1/glucagon agonist. In a stunning upset, Innovent Biologics reaches the finish line first — winning approval in China in June 2025 and proving that Asia's biotech industry has arrived on the world stage.

2018Discovery Year

Developed at Innovent Biologics in Suzhou, China

June 2025China NMPA Approval

First dual GLP-1/GCG agonist approved anywhere globally

34Amino Acids

Engineered dual-receptor binder

4,476 DaMolecular Weight

Daltons

Once WeeklyDosing

Subcutaneous injection

Eli LillyPartner

Global development collaboration since 2018

  • Dr. Michael Yu

    The Visionary Founder · Innovent Biologics, Suzhou, China

    Yu founded Innovent Biologics in 2011 with a bold mission: bring world-class biopharmaceutical innovation to China. In 2018, he led the company's strategic decision to pursue the dual GLP-1/glucagon agonist approach — betting that a Chinese biotech could reach the market faster than entrenched global competitors. His partnership with Eli Lilly in 2018 provided resources and expertise while Innovent controlled speed and regulatory strategy.

    We believed China's regulatory pathway could move faster if we had the right science and execution. The global giants were moving slowly because they had too many medicines in the pipeline. We could focus entirely on this one breakthrough.
  • Dr. Wenying Yang

    The Clinical Champion · China-Japan Friendship Hospital, Beijing

    Yang served as principal investigator for the GLORY Phase 3 trials across multiple Chinese centers. She designed rigorous protocols that would satisfy both Chinese regulators and the global scientific community. Her leadership in conducting the GLORY-1 trial — which met all primary endpoints in January 2024 — provided the clinical evidence that convinced China's NMPA to approve mazdutide for obesity, making history.

    We had to prove that a Chinese-developed drug could meet the highest global standards. Every patient enrolled, every data point mattered. When GLORY-1 showed such strong results, it validated that Innovent and our regulatory strategy were on the right path.
  • Dr. Lei Qian

    The Scientist Behind the Science · Innovent Biologics, Suzhou, China

    Qian led the scientific team that engineered mazdutide's unique dual-receptor binding properties. Starting from 2018, his group screened thousands of peptide sequences to find the optimal structure that could activate both GLP-1 and glucagon receptors with the right balance of potency. His work proved that Chinese scientists could compete in cutting-edge biotechnology innovation.

    The challenge was not just making something that binds two receptors — it was making something that binds them perfectly, with exactly the right potency at each target. We ran thousands of experiments to get it right.
  • Eli Lilly Partnership Team

    The Global Development Strategist · Eli Lilly and Company, Indianapolis, USA

    Eli Lilly entered a collaboration with Innovent Biologics in 2018, providing clinical trial expertise, regulatory guidance, and resources for the global Phase 2 program running in US and European markets. While Innovent moved rapidly through China's pathway, Lilly's team handled the more complex multi-country trials, planning for eventual global expansion.

    We recognized that Innovent had speed and focus. We brought global expertise and patient reach. Together, we could bring this breakthrough medicine to patients worldwide faster than any single company could alone.

  1. The Discovery

    The Asian Opportunity

    A Global Crisis Hits Home

    Key moment

    Chinese obesity rates triple between 2000 and 2015

    The obesity epidemic was growing fastest in Asia. China's population of 1.4 billion people faced an explosion of weight-related disease. Between 2000 and 2015, obesity rates among Chinese adults tripled. Type 2 diabetes became the nation's leading metabolic disorder, affecting over 110 million people by 2018.

    Meanwhile, Western pharmaceutical companies dominated GLP-1 drug development. Novo Nordisk had liraglutide. Novo Nordisk was preparing to launch semaglutide (Ozempic). Eli Lilly was developing tirzepatide. These companies moved slowly because they had massive research pipelines with hundreds of other drugs in development. Each therapy took 10-15 years to move from concept to approval in the United States.

    Innovent Biologics, founded in 2011 by Michael Yu, saw a different opportunity. China's healthcare system wanted innovation, and China's regulatory agency — the National Medical Products Administration (NMPA) — was becoming faster and more efficient at approving breakthrough medicines. If a Chinese biotech could develop something faster than global giants, it could win approval in China years before the West. And then Eli Lilly could take that approved medicine global.

  2. The Breakthrough

    The Dual-Target Bet

    A Strategy Nobody Had Approved Yet

    Key moment

    IBI362/mazdutide identified as lead dual-receptor agonist candidate

    In 2018, Innovent Biologics made a bold scientific and strategic decision. Instead of copying what Western competitors were doing — developing single-target GLP-1 agonists — they would develop something more powerful: a peptide that activated both GLP-1 and glucagon receptors at the same time.

    The science was based on emerging evidence that combining two gut hormones could produce better metabolic effects than either one alone. Glucagon naturally increases energy expenditure and fat burning. GLP-1 reduces appetite and lowers blood sugar. Why not activate both simultaneously?

    Dr. Lei Qian's research team began screening thousands of peptide sequences. Each candidate had to bind strongly to both receptors while being stable enough to be manufactured and formulated as an injection. The team tested amino acid sequences, tested different chain lengths, tested different attachment points for stability-enhancing modifications. By 2019, they had identified a lead candidate: IBI362, which would become known as mazdutide.

    That same year, Innovent announced a collaboration with Eli Lilly to co-develop mazdutide. Lilly provided resources and clinical trial expertise; Innovent kept control of the Chinese regulatory pathway. This partnership gave Innovent the financial firepower to run rapid, rigorous Phase 1 and Phase 2 trials.

  3. The Trials

    The Race Accelerates

    Clinical Proof and Competition Looms

    Key moment

    GLORY-1 shows 15-18% average weight loss — exceeds expectations

    Phase 1 trials in 2020-2021 showed that mazdutide was safe and well-tolerated. Early weight loss data was impressive. At higher doses, patients lost up to 6.4% of their body weight in just 12 weeks — better than expected for this early phase. Innovent moved forward aggressively.

    The GLORY Phase 3 trial program launched in China. GLORY-1 would test mazdutide in patients with obesity. The trial enrolled over 500 patients across multiple Chinese centers, with Dr. Wenying Yang as principal investigator. The primary endpoint was weight loss at 52 weeks.

    But competition was heating up. Semaglutide and tirzepatide were also filing for approval in China. The race was no longer just about good science — it was about speed and execution. Innovent had one advantage: they could move through China's regulatory system faster than multinational companies with complex global approval timelines.

    In January 2024, GLORY-1 results were announced: mazdutide-treated patients lost an average of 15-18% of their body weight, with some achieving over 20% loss. All primary and secondary endpoints were met. The data was strong enough that Innovent immediately submitted a New Drug Application (NDA) to China's NMPA in February 2024 for chronic weight management.

    Simultaneously, the DREAMS Phase 3 trial program was recruiting patients with type 2 diabetes, testing whether mazdutide could also serve as a diabetes treatment. Dr. Yang expanded her clinical leadership to oversee these trials as well.

  4. The Crisis

    Victory and Vindication

    The World's First Dual-Agonist Approval

    Key moment

    June 2025: First-ever dual GLP-1/GCG agonist approval globally

    For nearly two decades, drug companies had pursued single-target strategies. GLP-1 alone, GIP alone, glucagon alone. Each worked, but each had limitations. Mazdutide proved that the dual-target approach was not just possible — it was superior.

    In June 2025, China's NMPA approved mazdutide for chronic weight management, making it the first dual GLP-1/glucagon receptor agonist approved anywhere in the world. Western regulatory agencies had not yet approved any dual-agonist in this class. By moving fast in China, Innovent Biologics had beaten Novo Nordisk, Roche, Amgen, Merck, and all other global competitors to this breakthrough.

    The significance was historic. For the first time, a Chinese biotech company had developed a novel drug class entirely independently and brought it to market before global giants. It proved that Asia's scientific innovation capability had matured. Innovent Biologics, listed on Hong Kong Stock Exchange (HKEX: 01801), demonstrated that Chinese companies could compete at the highest level of biotech.

    In September 2025, just three months after the obesity approval, China's NMPA approved mazdutide for type 2 diabetes based on the DREAMS trial results. Patients with diabetes saw improvements in blood sugar control with the added benefit of weight loss — a powerful combination.

    Meanwhile, Eli Lilly's global Phase 2 trials continue in the United States and Europe. If those trials succeed, mazdutide could become available to patients worldwide by 2027-2028, potentially extending Innovent's innovation lead even into global markets.

  5. The Legacy

    The Global Future

    From China to the World

    Key moment

    Mazdutide approval catalyzes shift in global pharmaceutical innovation leadership

    Mazdutide represents a turning point in the global pharmaceutical industry. For decades, the United States and Europe controlled drug development. Now, China is not just manufacturing generic medicines — it is inventing new drug classes.

    The approvals in China are just the beginning. Eli Lilly is running Phase 2 trials in the US and Europe. If those trials succeed, regulatory submissions could follow in 2026-2027. The US FDA and European Medicines Agency will evaluate whether mazdutide offers advantages over existing GLP-1 and tirzepatide medicines. Early evidence suggests it might — the dual-receptor activation provides weight loss and metabolic improvements that single-target drugs cannot match.

    Innovent Biologics is also expanding mazdutide's clinical development. In December 2025, the company began a Phase 1b trial in Chinese adolescents with obesity — testing whether this breakthrough can help younger patients before they develop type 2 diabetes and other complications.

    The competitive landscape is shifting. Roche is developing a dual GLP-1/GIP agonist. Novo Nordisk is testing triple-hormone combinations. But mazdutide is already approved and in patients' hands in China. That head start — being five years ahead of competitors in real-world use — could define the market for the next decade.

    Most importantly, mazdutide proves that breakthroughs can come from anywhere. They don't have to originate in Boston or San Francisco. A young company in Suzhou can dream as big as the giants, execute faster, and reach patients first. The future of medicine is no longer dominated by a single geography — it belongs to whoever can combine excellent science with rapid execution.

15 milestones, 2011 – 2027-2028.

  1. 2011Innovent Biologics founded by Dr. Michael Yu with vision to develop world-class Chinese biopharmaceuticals
  2. 2018Innovent begins development of IBI362 (mazdutide) as dual GLP-1/glucagon agonist
  3. 2018Eli Lilly enters collaboration with Innovent Biologics for global co-development of mazdutide
  4. 2019Phase 1 clinical trials of mazdutide begin; safety and early efficacy data show promise
  5. 2020Phase 1b trials demonstrate up to 6.4% weight loss at higher doses over 12 weeks
  6. 2021GLORY Phase 3 trial program launches for obesity indication in China with 500+ patients
  7. 2021DREAMS Phase 3 trial program launches for type 2 diabetes indication in China
  8. 2023Eli Lilly initiates Phase 2 trials in United States and Europe
  9. January 2024GLORY-1 trial meets primary endpoint: 15-18% average weight loss at 52 weeks
  10. February 2024Innovent submits New Drug Application (NDA) to China NMPA for chronic weight management
  11. June 2025Historic approval: NMPA approves mazdutide — first dual GLP-1/GCG agonist approved globally
  12. September 2025NMPA approves mazdutide for type 2 diabetes based on DREAMS trial results
  13. December 2025Phase 1b trials begin testing mazdutide in Chinese adolescents with obesity
  14. 2026-2027Expected regulatory submissions in US and Europe based on Phase 2 trial results
  15. 2027-2028Potential FDA and EMA approvals would expand access to mazdutide globally

Mazdutide is a dual agonist — a single molecule that activates two different receptors in your body at the same time. It binds strongly to GLP-1 receptors (which reduce appetite and lower blood sugar) and glucagon receptors (which increase energy burning and fat loss). This dual activation produces a more powerful metabolic effect than single-target drugs. It's like hitting two metabolic brakes at once instead of just one.

Molecular structure

Amino Acids
34
Molecular Weight
4,476 Da
Chemical Formula
C₂₀₇H₃₁₇N₄₅O₆₅
Receptor Targets
GLP-1 + Glucagon (Dual)
PubChem CID
167312357
Dosing Frequency
Once Weekly Injection

18%Average Weight Loss

GLORY-1 trial at 52 weeks

First-EverDual GLP-1/GCG Agonist Approved

Globally approved in June 2025

2Approved Indications in China

Obesity (June 2025) and Type 2 Diabetes (Sept 2025)

500M+Potential Patients Treatable

In China alone, across obesity and diabetes

Real stories, real lives

  • Wang Wei (胜清)

    I weighed 95 kilograms and was pre-diabetic. I'd tried every diet, every weight loss clinic in Beijing. Nothing worked long-term. When I enrolled in the GLORY trial, I was skeptical — so many medicines had failed before. But mazdutide was different. After six months, I'd lost 15 kilograms. My appetite had changed completely. I don't constantly think about food anymore. My blood sugar numbers came down, my blood pressure improved. My daughter said I looked ten years younger. For the first time, I feel like my body is cooperating with me instead of fighting me.
  • Li Jing (李静)

    I was on three diabetes medications and still struggling with my numbers. I gained weight despite trying to exercise and eat healthy — it's like my body was broken. When my doctor told me about the DREAMS trial, I joined even though I was nervous about a new medicine. Mazdutide changed everything. After five months, my blood sugar was the best it's been in five years. I lost 12 kilograms without restricting my diet. My doctor reduced my insulin dose significantly. More importantly, I have energy again. I can play with my grandchildren without getting exhausted. This medicine gave me my life back.

The future of Mazdutide

  • Global FDA and EMA ApprovalsPhase 2 Ongoing (2025-2026)

    Eli Lilly Phase 2 trials in US and Europe continue. If successful, regulatory submissions could occur in 2026-2027 with potential approvals by 2027-2028, bringing mazdutide to Western patients

  • Adolescent Obesity ProgramPhase 1b (Starting Dec 2025)

    Testing mazdutide in Chinese teenagers with obesity to prevent progression to type 2 diabetes and metabolic complications. This could expand the addressable market significantly

  • Combination StudiesFuture Clinical Trials

    Research into combining mazdutide with other metabolic medicines or strategies to achieve even greater weight loss and metabolic improvement in hard-to-treat populations

  • Expanding IndicationsClinical Development

    Potential trials testing mazdutide for heart failure, liver disease, kidney disease, and other metabolic complications of obesity and diabetes — similar to how GLP-1 is being expanded beyond initial indications

Be inspired

The story of Mazdutide is ultimately about the relentless pursuit of better medicine for humanity.

Continue the legacy. The next breakthrough could be yours.

Mazdutide Chronicles. Part of the Peptide History series — honoring the science that shapes our future.

This content is for educational purposes only and should not be considered medical advice.